Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype
Jorge Rebola(Champalimaud Foundation), Antonio López-Beltrán(University of Córdoba), Ana Blanca(Instituto Maimónides de Investigación Biomédica de Córdoba), Vanessa Henriques(Champalimaud Foundation), Rodolfo Montironi(Marche Polytechnic University), Alessia Cimadamore(University of Udine), Liang Cheng(Brown University), Paula Lobato-Faria(Universidade Nova de Lisboa), Pedro Aguiar(Universidade Nova de Lisboa)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
June 25, 2019
Cited by 53
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289